DEF 14A: Stryker Corporation Announces Details for 2024 Annual Shareholder Meeting

Stryker Corporation's definitive proxy statement outlines details for the 2024 annual shareholder meeting, including voting matters, director nominees, executive compensation, and corporate governance practices.

Summary

• Stryker Corporation will hold its annual shareholder meeting virtually on May 9, 2024, at 9:30 a.m. Eastern Time.
• Shareholders of record as of March 11, 2024, are entitled to vote on the election of ten directors, ratification of Ernst & Young LLP as the independent registered public accounting firm, an advisory vote on executive compensation, and a shareholder proposal on transparency in political spending.
• The Board recommends voting for the election of directors, ratification of the accounting firm, and approval of executive compensation, but against the shareholder proposal on political spending.
• The proxy statement details the backgrounds and qualifications of the director nominees, including new nominee Rachel Ruggeri.
• Executive compensation practices are discussed, emphasizing pay-for-performance and alignment with shareholder interests; in 2023, variable and stock-based compensation averaged 89% of total direct compensation for NEOs.
• The company's financial performance for 2023 is highlighted, with net sales of $20.498 billion, net earnings of $3.165 billion, and adjusted net earnings of $4.066 billion.
• The proxy statement also covers corporate governance practices, board committees, stock ownership information, and related party transactions.
• The company's approach to environmental, social, and governance (ESG) matters is outlined, including commitments to carbon neutrality and supplier engagement.
• The Compensation and Human Capital Committee made downward adjustments to the final 2023 bonus payouts for the NEOs to more closely approximate the average bonus payout level for other bonus eligible employees in the Company.
• The payout related to the 2021 grant of performance stock units was 148% of target as a result of performance that reached the maximum goal for average reported net sales growth relative to a comparison group of companies and slightly below the target goal for average adjusted net earnings per diluted share growth.

Sentiment

Score: 7

Explanation: The document is primarily factual and informative, presenting details about the annual meeting, director nominees, executive compensation, and corporate governance. The sentiment is neutral to slightly positive, reflecting the company's strong financial performance and commitment to ESG matters.

Positives

• Stryker achieved strong financial results in 2023, with net sales of $20.498 billion and adjusted net earnings of $4.066 billion.
• The company emphasizes pay-for-performance, with a significant portion of executive compensation tied to company performance and shareholder value.
• Stryker has a comprehensive corporate governance framework, including independent directors, board committees, and risk oversight.
• The company is committed to ESG matters, with specific goals for carbon neutrality, renewable electricity, and supplier engagement.
• The company's executive compensation programs are designed to attract, motivate, and retain talented executives.
• The payout related to the 2021 grant of performance stock units was 148% of target as a result of performance that reached the maximum goal for average reported net sales growth relative to a comparison group of companies and slightly below the target goal for average adjusted net earnings per diluted share growth.

Negatives

• A shareholder proposal requests greater transparency in political spending, indicating potential concerns about the company's current disclosure practices.
• The Compensation and Human Capital Committee made downward adjustments to the final 2023 bonus payouts for the NEOs to more closely approximate the average bonus payout level for other bonus eligible employees in the Company.

Risks

• The company's ability to achieve its ESG commitments is subject to numerous risks and factors outside of its control.
• Forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially.
• The company faces risks related to economic conditions, competition, and regulatory changes.

Future Outlook

The proxy statement contains forward-looking statements based on current projections about operations, industry conditions, financial condition, and liquidity, which are subject to risks and uncertainties.

Management Comments

• We invite all shareholders to attend the virtual meeting.
• At the meeting, you will have the opportunity to ask questions of our management with respect to the matters to be voted on and will hear a report on our business.

Industry Context

Stryker monitors a comparison group of medical technology and other related companies to ensure that its compensation programs are within observed competitive practices.

Comparison to Industry Standards

• The comparison group companies used in the 2022 benchmarking study were: Abbott Laboratories, Boston Scientific Corporation, Quest Diagnostics Incorporated, Agilent Technologies, Inc., Danaher Corporation, Regeneron Pharmaceuticals, Inc., Amgen Inc., Eli Lilly and Company, Thermo Fisher Scientific Inc., Baxter International Inc., Gilead Sciences, Inc., Viatris Inc., Becton, Dickinson and Company, Laboratory Corporation of America Holdings, Zimmer Biomet Holdings, Inc., Biogen Inc., Medtronic plc.
• The comparison group was developed by Semler Brossy and members of our Human Resources department and approved by the Compensation and Human Capital Committee.
• The industry screening criteria used in the development of the comparison group were modestly expanded relative to prior years in order to identify additional suitable comparators in light of: (i) the limited number of companies of relevant size in the medical technology industry, and (ii) the continuing acquisition activity and consolidation within the comparison group.

Related Party Transactions

• The Board considered that the Company spent $360,000 in 2023 on functions and meetings held at hotel, restaurant and entertainment properties in Kalamazoo, Michigan (principally the Radisson Plaza Hotel) that are owned by Greenleaf Hospitality and that Stryker also reimbursed employees for hotel, restaurant and other expenses incurred by them at such properties while they were in Kalamazoo for business meetings.
• Management of Stryker has been advised by Greenleaf Hospitality that Greenleaf Hospitality is 100% owned by Ms. Stryker's husband.
• The Board has determined that the relationship with Greenleaf Hospitality is not material under the circumstances, including the modest nature of the transactions compared to the total revenues of Stryker and Greenleaf Hospitality, the ordinary course status of the transactions and the arm's length nature of the transactions, including a Stryker discounted rate from Greenleaf Hospitality.

Stakeholder Impact

• Shareholders are encouraged to participate in the annual meeting and vote on important matters.
• Employees are impacted by the company's compensation and benefits programs.
• Customers benefit from the company's commitment to making healthcare better.
• Suppliers are engaged on ESG performance assessments.
• The company's ESG initiatives aim to positively impact people and the planet.

Next Steps

• Shareholders should review the proxy materials and vote their shares before the deadlines.
• Attend the virtual annual meeting on May 9, 2024, to ask questions and hear a report on the company's business.
• The Board will consider the results of the advisory vote on executive compensation in future determinations.

Key Dates

Keywords

proxy statement, shareholder meeting, executive compensation, corporate governance, director nominees, financial performance, ESG, political spending, audit committee, compensation committee